Abstract
The growing crisis of antibiotic resistance is placing increasing urgency on the search for novel therapeutics, and raises the new challenge of identifying drugs that will continue to work in the face of inevitable pathogen evolution. I will discuss new theory and data highlighting how interventions targeting bacterial social behaviours can cause selection for resistance to be reduced, or even reversed, opening a path towards the development of evolutionarily robust novel therapeutics.